Navigation Links
Bioheart Announces Plans to Advance LVAD + Muscle Stem Cells Clinical Trial
Date:12/8/2010

nfarctions and lower limb ischemia utilizing adipose (fat) derived cells.  Bioheart is focused on heart failure and has a building pipeline of product developments to assist care providers in treating and caring for these patients.

Forward-Looking Statements:Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities an
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
2. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
3. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
4. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
5. Leading Experts Endorse Biohearts Muscle Stem Cell MyoCell Therapy
6. Biohearts MyoCell Recognized as one of the Breakthrough Developments of 2010
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... new survey shows almost half (44%) of U.S. patients ... acute pain. (Logo: http://photos.prnewswire.com/prnh/20110816/DC52192LOGO-b ) ... Pain (P3) Survey, one of the largest pain management ... also show that this undertreatment was particularly prevalent among ...
... 2011 Cohera Medical, Inc.®, a rapidly growing medical ... Mark approval for its lead product, TissuGlu® ... to be sold in the European Union. ... large flap surgeries, such as abdominoplasties, that helps reduce ...
Cached Medicine Technology:New Survey Shows Moderate-to-Severe Acute Pain is Widely Undertreated, Especially Among Older Adults 2Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 2Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 3
(Date:4/23/2014)... of scientists led by a researcher from the Cancer ... University of Singapore has identified the cancer specific stem ... the possibility of developing new drugs for the treatment ... The research group, led by Dr Chan Shing Leng, ... first time that a cancer-specific variant of a cell ...
(Date:4/23/2014)... also known as Ritalin, may prevent the depletion of ... , a journal of the Association for Psychological Science. ... diet or trying to focus attention on a boring ... one potential explanation for this difficulty: Exerting self-control for ... exert self-control effectively on subsequent tasks. , "It is ...
(Date:4/22/2014)... the New Jersey Institute of Technology (NJIT) today ... the launch of the New Jersey Innovation Institute ... model for business innovation through the leveraging of ... U.S. Senator Cory Booker, Panasonic Corp. of North ... Lieutenant Governor Kim Guadagno, New Jersey Secretary of ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making ... . , A team of physician-scientists at UT ... (a hormone with natural anti-depressant properties) works inside the ... treatment for depression in the form of a neuroprotective ... published online in April,s issue of Molecular Psychiatry, ...
(Date:4/22/2014)... (April 22, 2014) The International Communication Association ... in Seattle, Washington. The theme of the 2014 ... in a networked and digital society. , Featuring ... by over 2,200 Communication scholars representing over 40 ... international communication conference in the world. This year,s ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... ... ... ... ...
... behind many countries in the use of electronic health ... and political leaders set targets for universal adoption, states ... Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj092189.pdf . ... in federal funds to develop integrated electronic health records, ...
... ... ... ... ...
... ... ... , ... HOUSTON , March 1 Despite Northstar ...
... ... Position , ... Ariz. (Vocus) February 28, 2010 -- Tom Rios has been promoted to Executive Director ... he had been Splendido’s director of accounting., , ,Rios will work with managers and ...
... ... ... ... ...
Cached Medicine News:Health News:Chlorella: A Green Whole Food That Can Help Improve the American Diet 2Health News:Chlorella: A Green Whole Food That Can Help Improve the American Diet 3Health News:George Lundberg, MD, Joins MedPage Today(R) as Editor-at-Large 2Health News:George Lundberg, MD, Joins MedPage Today(R) as Editor-at-Large 3Health News:George Lundberg, MD, Joins MedPage Today(R) as Editor-at-Large 4Health News:George Lundberg, MD, Joins MedPage Today(R) as Editor-at-Large 5Health News:Northstar Management Forecasts a Loss of $1.2 Million for 2010 at Its Palladium for Surgery -- Houston, Ltd. Centre 2Health News:Tom Rios Named Executive Director at Splendido 2Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 2Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 3Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 4Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 5Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 6Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: